Is MNPR or MRNA more undervalued in 2026?

CirclFi compares Monopar Therapeutics Inc. (MNPR) and Moderna, Inc. (MRNA) using 13 institutional-grade valuation models. MNPR has a Quality of Company score of 4.3/10 while MRNA scores 7.1/10.

Which is a better buy — MNPR or MRNA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MNPR and MRNA valuations compare?

MNPR at $64.43 and MRNA at $47.57 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MNPR vs MRNA Valuation Comparison 2026 — Intrinsic Value Analysis

MNPR

Biotechnology

Monopar Therapeutics Inc.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$64.43

Last close

Models

8/13

Active

MRNA

Biotechnology

Moderna, Inc.

Quality

7.1

out of 10

Value Trap

SAFE

Price

$47.57

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	MNPR Fair Value	MNPR Upside	MRNA Fair Value	MRNA Upside
Bayesian DCF	Intrinsic	$21.57	-66.5%	$131.00	+175.4%
Earnings Power Value	Intrinsic	—	—	$82.08	+80.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$6.18	-90.4%	$10.08	-78.7%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MNPR vs MRNA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MNPR vs MRNA — Which Stock Is More Undervalued?

MRNA scores higher with a 7.1/10 quality rating vs MNPR's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Monopar Therapeutics Inc. (MNPR) and Moderna, Inc. (MRNA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MNPR currently trades at $64.43 with a QOC of 4.3/10, while MRNA trades at $47.57 with a QOC of 7.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).